ILMNIllumina, Inc.
Price
+171%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, nothing alarming, demanding price, growth fading, the market undecided.
We are a global leader in sequencing- and array-based solutions for genetic and genomic analysis. Our products and services serve customers in a wide range of markets, enabling the adoption of genomic solutions in research and clinical settings. We were incorporated in California in April 1998 and reincorporated in Delaware in July 2000.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Illumina, Inc. (ILMN) reported revenue of $1.16B in Q2 2026 (quarter ended Jun 28, 2026), up 9.4% from the same quarter a year earlier. That came with a gross margin of 66% and net income of $207M (18% of revenue). For the full year FY2025, revenue was $4.34B (−0.7% year on year) and net income $850M. Its largest region in Q2 2026 was United States And Canada at $653M, 56% of the disclosed total, well ahead of EMEA at 32%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 17, 2026On August 17, 2026, Illumina, Inc. (“Illumina” or the “Company”) completed a public offering of $300,000,000 aggregate principal amount of its 4.950% notes due 2029 (the “Notes”)Other event · Form 8-K
- Aug 13, 2026Entry into Credit Agreement On August 13, 2026, Illumina, Inc. (“Illumina” or the “Company”) entered into a credit agreement (the “Credit Agreement”) among the Company, as the borrower, the lenders from time to time party thereto, Bank of America, N.A., as administrative agent, an issuing bank and the swingline …Material agreement entered · Form 8-K
- Aug 12, 2026On August 10, 2026, Illumina, Inc. (“Illumina”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein, for the issuance and sale by Illumina of $300,000,000 aggregate …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $1.16BThe company’s own SEC segment disclosure.
- United States And Canada$653.0M56%
- EMEA$368.0M32%
- Asia Pacific$82.0M7%
- China$56.0M5%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #7 of 21 by RyuScore